A systematic review and meta-analysis of the effect of melatonin, melatonin agonist and melatonin precursor on delirium prevention in the elderly medical and surgical inpatients
10th World congress on Dementia and Alzheimer’s Disease
August 16-17, 2018 | Copenhagen, Denmark
Kay Khaing
Hunter New England Health NSW, Australia
Scientific Tracks Abstracts : J Neurol Neurorehabil Res
Abstract:
Background and aims: Melatonin is a pineal gland
hormone synthesised within the pinealocytes. It is believed
to have a protective effect against delirium. This study
aimed to investigate the effects of melatonin, melatonin
receptor agonist and melatonin precursor on delirium
prevention in the elderly medical and surgical patients.
Methods: Controlled trials of melatonin, melatonin agonist
(ramelteon) and melatonin precursor (tryptophan) were included.
A meta-analysis with a random effects model was performed.
Findings: 7 studies (1515 participants) met the inclusion
criteria. Among medical patients, delirium risk reduced by
63% with Melatonin, 88% with Ramelteon and insignificantly
with tryptophan. Hallucination and nightmare were more
prevalent in patients taking melatonin.
Interpretation: Ramelteon and Melatonin were associated with
a fall in delirium incidence. But its benefit needs to be balanced
against its potential side effects of hallucinations and nightmares.
Biography:
Kay Khaing has completed MBBS at the age of 25 years from Institute of Medicine 2, Yangon, Myanmar and Master of Medicine (Clinical Epidemiology) from University of Sydney in 2016. She has completed Geriatric Fellowship in 2017 and is working as a Geriatrician
E-mail: dr.k.khaing@gmail.com
PDF HTML